Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 7/20 | 0.42 |
| ▸ | BRAF | P15056 | 8/20 | 0.42 |
| ▸ | LCK | P06239 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | TEK | Q02763 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | TEC | P42680 | 1/20 | 0.40 |
| ▸ | TXK | P42681 | 1/20 | 0.40 |
| ▸ | BMX | P51813 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079743 | 0.92 | BRAF (0.42) | BTKBRAFLCKKDRJAK3 | |
| SCHEMBL1083594 | 0.91 | BRAF (0.43) | BTKBRAFLCKKDRJAK3 | |
| SCHEMBL1077797 | 0.90 | BTK (0.42) | BTKBRAFLCKKDRJAK3 | |
| SCHEMBL1077406 | 0.90 | BRAF (0.44) | BTKBRAFLCKKDRJAK3 | |
| SCHEMBL1079234 | 0.89 | BRAF (0.41) | BTKBRAFLCKKDRJAK3 | |
| SCHEMBL1077186 | 0.89 | ABL1 (0.47) | BTKBRAFLCKTECTXK | |
| SCHEMBL1076762 | 0.89 | LCK (0.54) | BTKBRAFLCKKDRJAK3 | |
| SCHEMBL1076926 | 0.88 | LCK (0.48) | BTKBRAFLCKKDRJAK3 | |
| SCHEMBL1149020 | 0.88 | LCK (0.37) | BRAFLCKKDRJAK3MAPK14 | |
| SCHEMBL1076555 | 0.86 | BRAF (0.41) | BTKBRAFLCKKDRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269993-B1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269993-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | H1-2, H1-3, H1-0 | BTK 1837/4885BRAF 2498/4885LCK 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.